Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Medicenna Therapeutics Corp. has received approval from the European Medicines Agency (EMA) to expand its Phase 1/2 ABILITY-1 clinical trial of MDNA11, a novel immunotherapy treatment for advanced solid tumors, into the EU. Currently enrolling patients in the U.S., Canada, Australia, and Korea, this expansion is expected to accelerate patient enrollment and progress the trial, with data from the monotherapy and combination therapy expected in the second half of 2024. MDNA11 is distinguished by its unique mechanism that selectively activates immune cells effective in killing cancer cells while minimizing the stimulation of immunosuppressive cells.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
